Xin Changxing went to Nanjing and Suzhou to investigate the development of biopharmaceutical industry clusters

Accelerating the construction of strategic emerging industry clusters with international competitiveness is a major task entrusted to Jiangsu by General Secretary Xi Jinping. From February 12 to 13, Provincial Party Secretary Xin Changxing went to parks, enterprises and universities in Nanjing and Suzhou to investigate the development of biopharmaceutical industry clusters. He stressed that we must thoroughly study and implement the spirit of General Secretary Xi Jinping’s important speech on Jiangsu’s work, focus on the source of scientific and technological innovation, build a good industrial ecology, promote integrated cluster development, and build a more competitive highland for the innovation and development of biomedical medicine.

Kingsrui Biotechnology Co., Ltd. is a well-known life science product and service provider, incubating a number of unicorns and specialized and new “little giant” companies. Xinchangxing went into the showroom and production line to learn more about the company’s development history, the application of main business segments, cell and gene therapy products, AI technology empowerment, etc., encourage enterprises to gather first-class innovation teams, actively explore “AI+biopharmaceutical” technology, and improve R&D efficiency, launch innovative drugs based on new structures, new targets and new mechanisms. At Jiangyuan Andiko Positive Electronics Research and Development Co., Ltd., Xin Changxing listened to the introduction of the development trend of the domestic and foreign nuclear medical industry and learned about the R&D and production situation of the company. He pointed out that nuclear medical care has broad prospects in early diagnosis and precise treatment. On the premise of ensuring safety, we must develop more new drugs and high-end diagnosis and treatment equipment to better benefit the general public.

Suzhou Biopharma Industrial Park has gathered more than 620 innovative pharmaceutical companies, especially a group of multinational pharmaceutical companies investing in this area, and its comprehensive competitiveness ranks among the top similar parks in the country. Xin Changxing came to the exhibition center to listen to the introduction of the park’s operating model, corporate listing financing, overseas market expansion, etc., and affirmed the achievements made in persistently promoting the development of the biopharmaceutical industry over the years. He pointed out that biomedicine is a sunrise industry with high investment, high risks and long cycles. It is necessary to support enterprises’ innovative development and thriving growth in all stages such as R&D, clinical, manufacturing, and application. Pioneering Biology and Nawei Technology are enterprises nurtured by the park and are in a leading position in their respective fields. The company’s head said that Jiangsu has a good industrial ecology and a comfortable life, and is a highland for innovation and a blessed place for entrepreneurship. Xin Changxing said happily, you are focused on innovation and running a business, and we will do our best to provide services to solve everyone’s worries. Yasheng Pharmaceutical is committed to solving clinical problems in the fields of hematologic tumors. Xinchangxing visited laboratories and production bases, inquired about the sales of innovative drugs, the progress of products under development, etc., and encouraged enterprises to target the forefront of science and technology, grasp the global market, and lead the industry’s development and enhance their competitive advantages with continuous original results.

China Pharmaceutical University is known as the “cradle of China’s biomedical talents.” In the National Key Laboratory of Multi-Target Natural Drugs at the school, teachers and students concentrate their minds and explore unknown secrets. Xin Changxing carefully understood the situation of discipline construction, talent training, scientific and technological research, industry-university-research cooperation, and discussed with scientific researchers the prospects of the integration of biomanufacturing, artificial intelligence, and quantum computing, and praised the school for its deep integration into the development of Jiangsu biopharmaceutical industry clusters. He pointed out that biomedicine involves the cross-integration of multidisciplinary disciplines, and it is necessary to promote cutting-edge-oriented exploratory basic research, but also to accelerate market-oriented applied basic research. China Pharmaceutical University has distinctive characteristics and strong strength. It is an important source of biotechnology innovation and a strong support for Jiangsu’s development of the biopharmaceutical industry. We hope that the school will give full play to the leading role of national key laboratories, collaborate with scientific research institutions, enterprises, etc. to form an innovation consortium, and open up new fields and new tracks.

During the investigation, Xin Changxing presided over a symposium. The responsible persons of the Provincial Department of Industry and Information Technology and Suzhou City introduced the construction of biomedical clusters. The responsible persons of BeiGene, Nanwei Medical Technology, Hengrui Medicine, Yangzijiang Pharmaceutical, Nanjing Jiangbei New District Biomedical Public Service Platform, and Suzhou Innovation Investment Group were based on their foothold. The front line of production and research and development put forward opinions and suggestions. Xin Changxing had an in-depth exchange with everyone. He said that his speech not only reflected his keen perception of cutting-edge fields, but also revealed his confidence and determination to promote the high-quality development of the biopharmaceutical industry. The relevant provincial departments should carefully sort out opinions and suggestions, come up with practical and effective methods, and serve enterprises with all their hearts and emotions and strengthen the industry.

Xin Changxing emphasized that biomedicine is a strategic emerging industry that concerns the national economy and people’s livelihood and national security, and is undergoing disruptive changes. We must focus on the source of scientific and technological innovation, improve the level of innovation platform, overcome key core technologies with the tenacity of “two years of hard work”, promote the timely transformation of results into new products and new industries, and enhance the health and well-being of the people. We must focus on key industrial chains such as biopharmaceuticals, chemical drugs, traditional Chinese medicines, and medical devices, strengthen coordination among enterprises, industrial chains, and industrial clusters, give full play to the leading role of chain leaders, guide small and medium-sized enterprises to deepen their efforts in subdivided fields, and strengthen their efforts Greater results have been achieved on the chain replenishment and extension of the chain. We must provide precise financing support, continuously optimize the policy environment, gather more outstanding talents, and cultivate the competitiveness of industrial clusters with stronger guarantees and better environment.